Abstract
Colorectal cancer is a leading cause of death by cancer in the western world. Present oncological treatments have relatively little impact on long term survival and hope is pinned on screening. Current population-based screening methods are insufficient in reducing colorectal cancer deaths, therefore new approaches are needed. One approach is chemoprevention, which targets specific signalling pathways to interfere in the process of carcinogenesis. However, it is of great importance to critically assess the benefits of chemoprevention in comparison to its risk and inconvenience. It is unlikely that chemoprevention can be used in a wide unselected population, but is more favourable in high risk groups such as individuals especially susceptible to neoplasia because of environmental risk factors, patients with inflammatory bowel disease, those with a hereditary predisposition to CRC (FAP, Lynch, HNPCC) and patients with a previous history of colorectal cancer or adenomatous polyps. CRC is not one disease but a heterogeneous group of diseases with different underlying molecular mechanisms. Both prevention and therapy needs to be tailored to the molecular subtype of the cancer in question. This review summarises the evidence for the chemopreventive efficacy of the major agents investigated to date and their proposed molecular mechanism(s) of action.
Keywords: Chemoprevention, colorectal cancer, molecular mechanisms
Current Cancer Therapy Reviews
Title: Chemoprevention of Colorectal Cancer: Progress or Pipedream?
Volume: 6 Issue: 2
Author(s): Rutger J. Jacobs, Liudmila L. Kodach and James C.H. Hardwick
Affiliation:
Keywords: Chemoprevention, colorectal cancer, molecular mechanisms
Abstract: Colorectal cancer is a leading cause of death by cancer in the western world. Present oncological treatments have relatively little impact on long term survival and hope is pinned on screening. Current population-based screening methods are insufficient in reducing colorectal cancer deaths, therefore new approaches are needed. One approach is chemoprevention, which targets specific signalling pathways to interfere in the process of carcinogenesis. However, it is of great importance to critically assess the benefits of chemoprevention in comparison to its risk and inconvenience. It is unlikely that chemoprevention can be used in a wide unselected population, but is more favourable in high risk groups such as individuals especially susceptible to neoplasia because of environmental risk factors, patients with inflammatory bowel disease, those with a hereditary predisposition to CRC (FAP, Lynch, HNPCC) and patients with a previous history of colorectal cancer or adenomatous polyps. CRC is not one disease but a heterogeneous group of diseases with different underlying molecular mechanisms. Both prevention and therapy needs to be tailored to the molecular subtype of the cancer in question. This review summarises the evidence for the chemopreventive efficacy of the major agents investigated to date and their proposed molecular mechanism(s) of action.
Export Options
About this article
Cite this article as:
J. Jacobs Rutger, L. Kodach Liudmila and C.H. Hardwick James, Chemoprevention of Colorectal Cancer: Progress or Pipedream?, Current Cancer Therapy Reviews 2010; 6 (2) . https://dx.doi.org/10.2174/157339410791202510
DOI https://dx.doi.org/10.2174/157339410791202510 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
1,3,5-Triazine Analogs: A Potent Anticancer Scaffold
Current Signal Transduction Therapy Natural DNA Intercalators as Promising Therapeutics for Cancer and Infectious Diseases
Current Cancer Drug Targets Targeting Ras-RAF-ERK and its Interactive Pathways as a Novel Therapy for Malignant Gliomas
Current Cancer Drug Targets Attenuated Oncolytic Measles Virus Strains as Cancer Therapeutics
Current Pharmaceutical Biotechnology Before and After Preeclampsia: What Biomarkers are there?
Current Women`s Health Reviews Detection of Tumor Markers with ProteinChip® Technology
Current Pharmaceutical Biotechnology Paeonol, a Powerful Natural Product with Broad Biological Spectra by Inhibiting Inflammatory Pathway
Current Traditional Medicine Xenobiotic-Induced Transcriptional Regulation of Xenobiotic Metabolizing Enzymes of the Cytochrome P450 Superfamily in Human Extrahepatic Tissues
Current Drug Metabolism Predicting Protein-Ligand Interactions Based on Chemical Preference Features with its Application to New D-Amino Acid Oxidase Inhibitor Discovery
Current Pharmaceutical Design Docking and Molecular Dynamics Study on the Inhibitory Activity of Novel Inhibitors on Epidermal Growth Factor Receptor (EGFR)
Medicinal Chemistry Recent Developments in Protein and Cell-Targeted Aptamer Selection and Applications
Current Medicinal Chemistry In Silico Target Identification and Molecular Docking Studies of Natural Cytotoxic Compound Borivilianoside H
Current Biotechnology VEGF Signaling Regulates Cofilin and the Arp2/3-complex within the Axonal Growth Cone
Current Neurovascular Research A Review of AEG-1 Oncogene Regulating MicroRNA Expression in Colon Cancer Progression
Endocrine, Metabolic & Immune Disorders - Drug Targets Current State of the Art for Survival Prediction in Cancer Using Data Mining Techniques
Current Bioinformatics NADPH Oxidases and Inflammatory Bowel Disease
Current Medicinal Chemistry Targeted Therapies in the Treatment of Advanced Renal Cell Carcinoma
Recent Patents on Anti-Cancer Drug Discovery Pharmacogenetics, Pharmacogenomics and Epigenetics of Nrf2-regulated Xenobioticmetabolizing Enzymes and Transporters by Dietary Phytochemical and Cancer Chemoprevention
Current Drug Metabolism Application of Phage Display Technology to Cancer Research
Current Pharmaceutical Biotechnology Novel Monocyte Biomarkers of Atherogenic Conditions
Current Pharmaceutical Design